216 related articles for article (PubMed ID: 37591845)
21. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
Schinke C; Poos AM; Bauer M; John L; Johnson S; Deshpande S; Carrillo L; Alapat D; Rasche L; Thanendrarajan S; Zangari M; Al Hadidi S; van Rhee F; Davies F; Raab MS; Morgan G; Weinhold N
Blood Adv; 2022 Nov; 6(22):5873-5883. PubMed ID: 35977111
[TBL] [Abstract][Full Text] [Related]
22. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.
Melchor L; Brioli A; Wardell CP; Murison A; Potter NE; Kaiser MF; Fryer RA; Johnson DC; Begum DB; Hulkki Wilson S; Vijayaraghavan G; Titley I; Cavo M; Davies FE; Walker BA; Morgan GJ
Leukemia; 2014 Aug; 28(8):1705-15. PubMed ID: 24480973
[TBL] [Abstract][Full Text] [Related]
23. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Rustad EH; Misund K; Bernard E; Coward E; Yellapantula VD; Hultcrantz M; Ho C; Kazandjian D; Korde N; Mailankody S; Keats JJ; Akhlaghi T; Viny AD; Mayman DJ; Carroll K; Patel M; Famulare CA; Op Bruinink DH; Hutt K; Jacobsen A; Huang Y; Miller JE; Maura F; Papaemmanuil E; Waage A; Arcila ME; Landgren O
Am J Hematol; 2019 Dec; 94(12):1364-1373. PubMed ID: 31571261
[TBL] [Abstract][Full Text] [Related]
24. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich MJ; Neri P; Kehl N; Michel J; Steiger S; Kilian M; Leblay N; Maity R; Sankowski R; Lee H; Barakat E; Ahn S; Weinhold N; Rippe K; Bunse L; Platten M; Goldschmidt H; Müller-Tidow C; Raab MS; Bahlis NJ
Cancer Cell; 2023 Apr; 41(4):711-725.e6. PubMed ID: 36898378
[TBL] [Abstract][Full Text] [Related]
25. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
[TBL] [Abstract][Full Text] [Related]
26. Profiling the Epigenetic Landscape of the Tumor Microenvironment Using Chromatin Immunoprecipitation Sequencing.
Fukano M; Alzial G; Lambert R; Deblois G
Methods Mol Biol; 2023; 2614():313-348. PubMed ID: 36587133
[TBL] [Abstract][Full Text] [Related]
27. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.
Merz M; Hu Q; Merz AMA; Wang J; Hutson N; Rondeau C; Celotto K; Belal A; Alberico R; Block AW; Mohammadpour H; Wallace PK; Tario J; Luce J; Glenn ST; Singh P; Samur M; Munshi N; Liu S; McCarthy PL; Wei L; Hillengass J
Blood Adv; 2023 Mar; 7(5):718-733. PubMed ID: 35868022
[TBL] [Abstract][Full Text] [Related]
28. The microenvironment and molecular biology of the multiple myeloma tumor.
Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
[TBL] [Abstract][Full Text] [Related]
29. BCR-ABL1-driven exosome-miR130b-3p-mediated gap-junction Cx43 MSC intercellular communications imply therapies of leukemic subclonal evolution.
Chai C; Sui K; Tang J; Yu H; Yang C; Zhang H; Li SC; Zhong JF; Wang Z; Zhang X
Theranostics; 2023; 13(12):3943-3963. PubMed ID: 37554265
[No Abstract] [Full Text] [Related]
30. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.
Paíno T; Paiva B; Sayagués JM; Mota I; Carvalheiro T; Corchete LA; Aires-Mejía I; Pérez JJ; Sanchez ML; Barcena P; Ocio EM; San-Segundo L; Sarasquete ME; García-Sanz R; Vidriales MB; Oriol A; Hernández MT; Echeveste MA; Paiva A; Blade J; Lahuerta JJ; Orfao A; Mateos MV; Gutiérrez NC; San-Miguel JF
Leukemia; 2015 May; 29(5):1186-94. PubMed ID: 25388955
[TBL] [Abstract][Full Text] [Related]
31. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.
de Jong MME; Kellermayer Z; Papazian N; Tahri S; Hofste Op Bruinink D; Hoogenboezem R; Sanders MA; van de Woestijne PC; Bos PK; Khandanpour C; Vermeulen J; Moreau P; van Duin M; Broijl A; Sonneveld P; Cupedo T
Nat Immunol; 2021 Jun; 22(6):769-780. PubMed ID: 34017122
[TBL] [Abstract][Full Text] [Related]
32. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients.
Zhao S; Wang Q; Ni K; Zhang P; Liu Y; Xie J; Ji W; Cheng C; Zhou Q
Front Immunol; 2023; 14():1263329. PubMed ID: 37727789
[TBL] [Abstract][Full Text] [Related]
33. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
34. Identification of long noncoding RNA
Chen T; Sun Z; Cui Y; Ji J; Li Y; Qu X
Hematology; 2023 Dec; 28(1):2164449. PubMed ID: 36657019
[TBL] [Abstract][Full Text] [Related]
35. The microenvironment in myeloma.
Lomas OC; Tahri S; Ghobrial IM
Curr Opin Oncol; 2020 Mar; 32(2):170-175. PubMed ID: 31895122
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
[TBL] [Abstract][Full Text] [Related]
37. Liquid Biopsies - the Clinics and the Molecules.
Kubaczková V; Sedlarikova L; Bollová B; Sandecká V; Stork M; Pour L; Sevcikova S
Klin Onkol; 2017; 30(Supplementum2):13-20. PubMed ID: 28903565
[TBL] [Abstract][Full Text] [Related]
38. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
39. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
40. Co-evolution of tumor and immune cells during progression of multiple myeloma.
Liu R; Gao Q; Foltz SM; Fowles JS; Yao L; Wang JT; Cao S; Sun H; Wendl MC; Sethuraman S; Weerasinghe A; Rettig MP; Storrs EP; Yoon CJ; Wyczalkowski MA; McMichael JF; Kohnen DR; King J; Goldsmith SR; O'Neal J; Fulton RS; Fronick CC; Ley TJ; Jayasinghe RG; Fiala MA; Oh ST; DiPersio JF; Vij R; Ding L
Nat Commun; 2021 May; 12(1):2559. PubMed ID: 33963182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
